Publications by authors named "F Michael Yakes"

Claim this Profile
T
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.
Ronan Le Moigne, Blake T Aftab, Stevan Djakovic, Eugen Dhimolea, Eduardo Valle, F Michael Yakes

Mol Cancer Ther· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083).
Han-Jie Zhou, Jinhai Wang, Bing Yao, Steve Wong, Stevan Djakovic, F Michael Yakes

J Med Chem· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis.
Daniel J Anderson, Ronan Le Moigne, Stevan Djakovic, Brajesh Kumar, Julie Rice, F Michael Yakes

Cancer Cell· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
Paul Foster, Kyoko Yamaguchi, Pin P Hsu, Fawn Qian, Xiangnan Du, F Michael Yakes

Mol Cancer Ther· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Peiwen Yu, A Douglas Laird, Xiangnan Du, Jianming Wu, Kwang-Ai Won, F Michael Yakes

Mol Cancer Ther· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis